Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table illustrates information about segment revenues, significant segment expenses, and segment net loss for the years ended December 31, 2024, 2023, and 2022 (in thousands):

	Years Ended December 31,
	2024		2023		2022
Revenues	$	450,712	$	331,412	$	270,827
Less1:
Cost of product sales	12,269		4,481		6,408
Research and development
Berotralstat	45,033		42,835		32,637
Factor D Program	24,072		94,517		174,234
BCX17725	32,417		19,133		—
Other research, preclinical and development costs	73,116		60,081		46,426
Selling, general and administrative	266,132		213,894		159,371
Royalty	216		180		186
Other segment items2	641		30,058		1,983
Interest income	(14,746)		(15,777)		(5,127)
Interest expense	98,516		108,239		99,092
Income tax expense	1,927		310		2,733
Segment net loss	(88,881)		(226,539)		(247,116)
Reconciliation of segment profit or loss:
Adjustments and reconciling items	—		—		—
Consolidated net loss	$	(88,881)	$	(226,539)	$	(247,116)
1 The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.
2 Other segment items included in Segment net loss include loss on extinguishment of debt and foreign currency losses, net.